FDA for the withdrawal of midodrine
| Author : Pierre Allain
||Date : 2010-10-25
FDA, in a note dated August 16, 2010, asks for the withdrawal from the market of midodrine (ProAmatine*) because its efficacy on clinical events has not been confirmed.
More information about midodrine and other vasoconstrictor agents with alpha-1 adrenergic effect.